Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
2.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

3.

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Bednasz CJ, Venuto CS, Ma Q, Morse GD.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):135-139. doi: 10.1002/cpdd.313. Review.

4.

Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver.

Ocque AJ, Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH.

Bioanalysis. 2016 Jul;8(13):1353-63. doi: 10.4155/bio-2016-0040. Epub 2016 Jun 9.

5.

Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD.

Future Virol. 2015;10(8):981-997.

Supplemental Content

Loading ...
Support Center